Switch theme
Sign up to access all valuation multiples
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
2000
173
LTM Revenue $38.8M
LTM EBITDA -$12.8M
$311M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alpha Teknova has a last 12-month revenue (LTM) of $38.8M and a last 12-month EBITDA of -$12.8M.
In the most recent fiscal year, Alpha Teknova achieved revenue of $37.7M and an EBITDA of -$19.6M.
Alpha Teknova expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alpha Teknova valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $38.8M | XXX | $37.7M | XXX | XXX | XXX |
| Gross Profit | $9.5M | XXX | $7.2M | XXX | XXX | XXX |
| Gross Margin | 25% | XXX | 19% | XXX | XXX | XXX |
| EBITDA | -$12.8M | XXX | -$19.6M | XXX | XXX | XXX |
| EBITDA Margin | -33% | XXX | -52% | XXX | XXX | XXX |
| EBIT | -$22.3M | XXX | -$26.1M | XXX | XXX | XXX |
| EBIT Margin | -58% | XXX | -69% | XXX | XXX | XXX |
| Net Profit | -$24.0M | XXX | -$26.7M | XXX | XXX | XXX |
| Net Margin | -62% | XXX | -71% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $9.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alpha Teknova's stock price is $6.
Alpha Teknova has current market cap of $308M, and EV of $311M.
See Alpha Teknova trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $311M | $308M | XXX | XXX | XXX | XXX | $-0.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alpha Teknova has market cap of $308M and EV of $311M.
Alpha Teknova's trades at 8.2x EV/Revenue multiple, and -15.9x EV/EBITDA.
Equity research analysts estimate Alpha Teknova's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alpha Teknova has a P/E ratio of -12.8x.
See valuation multiples for Alpha Teknova and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $308M | XXX | $308M | XXX | XXX | XXX |
| EV (current) | $311M | XXX | $311M | XXX | XXX | XXX |
| EV/Revenue | 8.0x | XXX | 8.2x | XXX | XXX | XXX |
| EV/EBITDA | -24.4x | XXX | -15.9x | XXX | XXX | XXX |
| EV/EBIT | -13.9x | XXX | -11.9x | XXX | XXX | XXX |
| EV/Gross Profit | 32.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -12.8x | XXX | -11.5x | XXX | XXX | XXX |
| EV/FCF | -24.0x | XXX | -23.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlpha Teknova's last 12 month revenue growth is 11%
Alpha Teknova's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Alpha Teknova's rule of 40 is -59% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alpha Teknova's rule of X is -6% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alpha Teknova and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | -33% | XXX | -52% | XXX | XXX | XXX |
| EBITDA Growth | -32% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -59% | XXX | -41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -6% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 88% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alpha Teknova acquired XXX companies to date.
Last acquisition by Alpha Teknova was XXXXXXXX, XXXXX XXXXX XXXXXX . Alpha Teknova acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alpha Teknova founded? | Alpha Teknova was founded in 2000. |
| Where is Alpha Teknova headquartered? | Alpha Teknova is headquartered in United States of America. |
| How many employees does Alpha Teknova have? | As of today, Alpha Teknova has 173 employees. |
| Who is the CEO of Alpha Teknova? | Alpha Teknova's CEO is Mr. Stephen Gunstream. |
| Is Alpha Teknova publicy listed? | Yes, Alpha Teknova is a public company listed on NAS. |
| What is the stock symbol of Alpha Teknova? | Alpha Teknova trades under TKNO ticker. |
| When did Alpha Teknova go public? | Alpha Teknova went public in 2021. |
| Who are competitors of Alpha Teknova? | Similar companies to Alpha Teknova include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Alpha Teknova? | Alpha Teknova's current market cap is $308M |
| What is the current revenue of Alpha Teknova? | Alpha Teknova's last 12 months revenue is $38.8M. |
| What is the current revenue growth of Alpha Teknova? | Alpha Teknova revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Alpha Teknova? | Current revenue multiple of Alpha Teknova is 8.0x. |
| Is Alpha Teknova profitable? | Yes, Alpha Teknova is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alpha Teknova? | Alpha Teknova's last 12 months EBITDA is -$12.8M. |
| What is Alpha Teknova's EBITDA margin? | Alpha Teknova's last 12 months EBITDA margin is -33%. |
| What is the current EV/EBITDA multiple of Alpha Teknova? | Current EBITDA multiple of Alpha Teknova is -24.4x. |
| What is the current FCF of Alpha Teknova? | Alpha Teknova's last 12 months FCF is -$12.9M. |
| What is Alpha Teknova's FCF margin? | Alpha Teknova's last 12 months FCF margin is -33%. |
| What is the current EV/FCF multiple of Alpha Teknova? | Current FCF multiple of Alpha Teknova is -24.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
